Search results

  • Full text

  • Document type

    • Publication year

  • Organisation

Results: 66
Number of items: 66
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P., & Van Kampen, A. H. C. (2020). Additional file 4 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673821.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 1 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673812.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 13 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673803.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P., & Van Kampen, A. H. C. (2020). Additional file 8 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673833.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 10 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673794.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 2 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673815.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 14 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673806.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 3 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673818.v1
  • Open Access
    Gjaltema, R. A. F., Goubert, D., Huisman, C., García Tobilla, C. P., Koncz, M., Jellema, P. G., Wu, D., Brouwer, U., Kiss, A., Verschure, P. J., Bank, R. A., & Rots, M. G. (2020). KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and is Resilient to TGFβ1 Activation. International Journal of Molecular Sciences, 21(10), Article 3634. https://doi.org/10.3390/ijms21103634
  • Open Access
    Soleimani Dodaran, M., Borgoni, S., Sofyali, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & van Kampen, A. H. C. (2020). Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer. BMC Cancer, 20, Article 676. https://doi.org/10.1186/s12885-020-07100-z
Page 2 of 7